East Hanover, NJ, United States of America

Mark Kagan


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

where 'Filed Patents' based on already Granted Patents

2 patents (USPTO):

Title: Mark Kagan: Innovator in Pharmaceutical Chemistry

Introduction

Mark Kagan is a notable inventor based in East Hanover, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of NEP inhibitors. With a total of 2 patents, Kagan's work has the potential to impact therapeutic applications significantly.

Latest Patents

Kagan's latest patents include the development of substituted bisphenyl butanoic ester derivatives as NEP inhibitors. The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R and R are defined herein. The disclosure also relates to a method for manufacturing the compounds and their therapeutic uses. Furthermore, it provides pharmaceutical compositions of the compounds and combinations of pharmacologically active agents with the compounds.

Career Highlights

Mark Kagan is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in drug development and therapeutic applications.

Collaborations

Kagan has collaborated with notable colleagues such as Yongshuai Chai and Sven Erik Godtfredsen, contributing to advancements in their shared field of expertise.

Conclusion

Mark Kagan's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the industry. His work continues to pave the way for advancements in therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…